Literature DB >> 26212020

Liver stiffness plus platelet count can be used to exclude high-risk oesophageal varices.

Nik S Ding1, Tin Nguyen1, David M Iser1, Thai Hong1, Emma Flanagan1, Avelyn Wong1, Lauren Luiz1, Jonathan Y C Tan2, James Fulforth3, Jacinta Holmes1, Marno Ryan1, Sally J Bell1, Paul V Desmond1, Stuart K Roberts2, John Lubel3,4, William Kemp2, Alexander J Thompson1.   

Abstract

BACKGROUND/AIMS: Endoscopic screening for high-risk gastro-oesophageal varices (GOV) is recommended for compensated cirrhotic patients with transient elastography identifying increasing numbers of patients with cirrhosis without portal hypertension. Using liver stiffness measurement (LSM) ± platelet count, the aim was to develop a simple clinical rule to exclude the presence of high-risk GOV in patients with Child-Pugh A cirrhosis.
METHODS: A retrospective analysis of 71 patients with Child-Pugh A cirrhosis diagnosed by transient elastography (LSM >13.6 kPa) who underwent screening gastroscopy was conducted. A predictive model using LSM ± platelet count was assessed to exclude the presence of high-risk GOV (diameter >5 mm and/or the presence of high-risk stigmata) and validated using a second cohort of 200 patients from two independent centres.
RESULTS: High-risk GOV were present in 10 (15%) and 16 (8%) of the training and validation cohorts, respectively, which was associated with LSM and Pl count (P < 0.05). A combined model based on LSM and Pl count was more accurate for excluding the presence of high-risk GOV than either alone (training cohort AUROC: 0.87 [0.77-0.96] vs. 0.78 [0.65-0.92] for LSM and 0.71 [0.52-0.90] for platelets) with the combination of LSM ≤25 kPa and Pl ≥100 having a NPV of 100% in both the training and validation cohorts. A total of 107 (39%) patients meet this criterion.
CONCLUSION: The combination of LSM ≤25 kPa and Pl ≥100 can be used in clinical practice to exclude the presence of high-risk GOV in patients with Child-Pugh A cirrhosis.
© 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  cirrhosis; elastography; hepatitis C virus; portal hypertension; surveillance

Mesh:

Year:  2015        PMID: 26212020     DOI: 10.1111/liv.12916

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  16 in total

Review 1.  Platelet count, spleen length, and platelet count-to-spleen length ratio for the diagnosis of oesophageal varices in people with chronic liver disease or portal vein thrombosis.

Authors:  Agostino Colli; Juan Cristóbal Gana; Jason Yap; Thomasin Adams-Webber; Natalie Rashkovan; Simon C Ling; Giovanni Casazza
Journal:  Cochrane Database Syst Rev       Date:  2017-04-26

2.  Validation of the Expanded Baveno-VI Criteria for Screening Gastroscopy in Asian Patients with Compensated Advanced Chronic Liver Disease.

Authors:  Pik-Eu Chang; Chee-Kiat Tan; Chang-Chuen Cheah; Weiquan Li; Wan Cheng Chow; Yu-Jun Wong
Journal:  Dig Dis Sci       Date:  2020-05-21       Impact factor: 3.199

3.  Validating, deconstructing and refining Baveno criteria for ruling out high-risk varices in patients with compensated cirrhosis.

Authors:  Parastoo Jangouk; Laura Turco; Ana De Oliveira; Filippo Schepis; Erica Villa; Guadalupe Garcia-Tsao
Journal:  Liver Int       Date:  2017-03-07       Impact factor: 5.828

4.  Assessing Baveno VI Criteria Using Liver Stiffness Measured with a 2D-Shear Wave Elastography Technique.

Authors:  Renata Fofiu; Felix Bende; Alina Popescu; Roxana Șirli; Bogdan Miuţescu; Ioan Sporea
Journal:  Diagnostics (Basel)       Date:  2021-04-21

Review 5.  Ultrasonography for Noninvasive Assessment of Portal Hypertension.

Authors:  Hitoshi Maruyama; Osamu Yokosuka
Journal:  Gut Liver       Date:  2017-07-15       Impact factor: 4.519

6.  Liver stiffness and serum markers for excluding high-risk varices in patients who do not meet Baveno VI criteria.

Authors:  Hong Zhou; Jun Long; Han Hu; Cai-Yun Tian; Shi-De Lin
Journal:  World J Gastroenterol       Date:  2019-09-21       Impact factor: 5.742

7.  Correlation of platelets count with endoscopic findings in a cohort of Egyptian patients with liver cirrhosis.

Authors:  Sherief Abd-Elsalam; Eslam Habba; Walaa Elkhalawany; Salwa Tawfeek; Hassan Elbatea; Ferial El-Kalla; Hanan Soliman; Samah Soliman; Mohamed Yousef; Abdelrahman Kobtan; Sally El Nawasany; Sheren Awny; Ibrahim Amer; Loai Mansour; Fatma Rizk
Journal:  Medicine (Baltimore)       Date:  2016-06       Impact factor: 1.889

Review 8.  Νon-invasive screening for esophageal varices in patients with liver cirrhosis.

Authors:  Andreas Karatzas; Christos Konstantakis; Ioanna Aggeletopoulou; Christina Kalogeropoulou; Konstantinos Thomopoulos; Christos Triantos
Journal:  Ann Gastroenterol       Date:  2018-03-03

9.  Austrian consensus guidelines on the management and treatment of portal hypertension (Billroth III).

Authors:  Thomas Reiberger; Andreas Püspök; Maria Schoder; Franziska Baumann-Durchschein; Theresa Bucsics; Christian Datz; Werner Dolak; Arnulf Ferlitsch; Armin Finkenstedt; Ivo Graziadei; Stephanie Hametner; Franz Karnel; Elisabeth Krones; Andreas Maieron; Mattias Mandorfer; Markus Peck-Radosavljevic; Florian Rainer; Philipp Schwabl; Vanessa Stadlbauer; Rudolf Stauber; Herbert Tilg; Michael Trauner; Heinz Zoller; Rainer Schöfl; Peter Fickert
Journal:  Wien Klin Wochenschr       Date:  2017-10-23       Impact factor: 1.704

10.  Validation of the Combined Model Based on Platelet Count and Albumin to Rule out High-Risk Varices in Liver Cirrhosis.

Authors:  Zhihui Duan; Li Li; Jinlong Li; Shengyun Zhou
Journal:  Biomed Res Int       Date:  2020-07-13       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.